Accepted: August 10, 2017 - Published online: November 28, 2017
https://doi.org/10.1176/appi.ajp.2017.17020223
Results:
Overall, 32.2% (95% CI=29.7–34.9) of patients with a substance-induced psychosis converted to either bipolar or schizophrenia-spectrum disorders. The highest conversion rate was found for cannabis-induced psychosis, with 47.4% (95% CI=42.7–52.3) converting to either schizophrenia or bipolar disorder. Young age was associated with a higher risk of converting to schizophrenia. Self-harm after a substance-induced psychosis was significantly linked to a higher risk of converting to both schizophrenia and bipolar disorder. Half the cases of conversion to schizophrenia occurred within 3.1 years after a substance-induced psychosis, and half the cases of conversion to bipolar disorder occurred within 4.4 years.
Conclusions:
Substance-induced psychosis is strongly associated with the development of severe mental illness, and a long follow-up period is needed to identify the majority of cases.
Addiction Science & Clinical Practice201712:9
https://doi.org/10.1186/s13722-017-0074-0
Background
Opioid use disorder (OUD) affects approximately 21.9 million people worldwide. This study aims to determine the association between age of onset of opioid use and comorbid disorders, both physical and psychiatric, in patients receiving methadone maintenance treatment (MMT) for OUD. Understanding this association may inform clinical practice about important prognostic factors of patients on MMT, enabling clinicians to identify high-risk patients.
Conclusion
Our study demonstrates that the younger one begins to use opioids, the greater their chance of having a physical or psychiatric co-morbidity. Understanding the risk posed by an earlier onset of opioid use for the later development of comorbid disorders informs clinical practice about important prognostic predictors and aids in the identification of high-risk patients.
(Prevention/delay/deny uptake still best practice)
Grant KS1, Petroff R2, Isoherranen N3, Stella N4, Burbacher TM5.
Abstract
The broad-based legalization of cannabis use has created a strong need to understand its impact on human health and behavior. The risks that may be associated with cannabis use, particularly for sensitive subgroups such as pregnant women, are difficult to define because of a paucity of dose-response data and the recent increase in cannabis potency. Although there is a large body of evidence detailing the mode of action of Δ9-tetrahydrocannabinol (THC) in adults, little work has focused on understanding how cannabis use during pregnancy may impact the development of the fetal nervous system and whether additional plant-derived cannabinoids might participate. This manuscript presents an overview of the historical and contemporary literature focused on the mode of action of THC in the developing brain, comparative pharmacokinetics in both pregnant and nonpregnant model systems and neurodevelopmental outcomes in exposed offspring. Despite growing public health significance, pharmacokinetic studies of THC have focused on nonpregnant adult subjects and there are few published reports on disposition parameters during pregnancy. Data from preclinical species show that THC readily crosses the placenta although fetal exposures appear lower than maternal exposures. The neurodevelopmental data in human and preclinical species suggest that prenatal exposure to THC may lead to subtle, persistent changes in targeted aspects of higher-level cognition and psychological well-being. There is an urgent need for well-controlled studies in humans and preclinical models on THC as a developmental neurotoxicant. Until more information is available, pregnant women should not assume that using cannabis during pregnancy is safe.
July 14, 2017 | Substance Use Disorder, Addiction By Ruby S. Grewal, MD and Tony P. George, MD, FRCPC
Cannabis is the most widely used illicit drug in the United States, and trends show increasing use in the general population. As cannabis consumption rises, there has been significant emerging evidence for cannabis-related risks to health.1
Numerous lines of evidence suggest a correlation between cannabis consumption and a variety of psychiatric conditions, including cannabis-induced psychosis (CIP). While it can be difficult to differentiate CIP from other psychoses, CIP holds distinguishing characteristics, which may aid in its diagnosis. Given the increasing push toward cannabis legalization, assessing CIP and employing timely treatments is critical.
Specifically in youth, there is a direct relationship between cannabis use and its risks. The lack of knowledge surrounding its detrimental effects, combined with misunderstandings related to its therapeutic effects, has potential for catastrophic results
Taking Action - Stopping Ice
dontlegalisedrugs.org
daca.org.au
drugabuse.gov
ibhinc.org
cannabissupport.com.au
globaldrugpolicy.com
fare.org.au
drugfree.org.au
preventteendruguse.org
United Nations Office of Drugs & Crime: Drug Prevention & Treatment
Medicinal Cannabis –
Government Management
Access to medicinal Cannabis Products (TGA)
https://www.tga.gov.au/access-medicinal-cannabis-products
Access to medicinal cannabis products: steps to using access ...
https://www.tga.gov.au/access-medicinal-cannabis-products-steps-using-access-schemes
https://www.tga.gov.au/medicinal-cannabis-products-overview-regulation
https://www.tga.gov.au/form/medicinal-cannabis-products
United Nations: Drug Use and Health Outcomes
UNODC Drug Indicator Statistics
Presentations, Statements & Conference Resources from WFAD 2018 Forum
More detoxification & rehabilitation that gets illicit drug users drug free.
Court ordered and supervised detoxification & rehabilitation.
Less illicit drug users, drug pushers and drug related crimes.